Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
NCT03301506
·
clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
340
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Biliary Cirrhosis
Interventions
DRUG:
Seladelpar 5 mg Capsule
DRUG:
Seladelpar 10 mg Capsule
Sponsor
Gilead Sciences